OptimizeRx Launches Programmatic Access to Authenticated EHR Advertising at Scale
Rhea-AI Summary
OptimizeRx (Nasdaq: OPRX) launched a new programmatic connection between its proprietary EHR network and demand-side platforms (DSPs), allowing life sciences media buyers to activate authenticated, point-of-care EHR campaigns directly within existing programmatic workflows.
The launch provides access to EHR inventory previously unavailable at scale, while opening OptimizeRx to the broader programmatic market, estimated at 90% of total U.S. digital display ad spend and helping DSPs pursue a share of the $19B+ pharma digital ad market.
AI-generated analysis. Not financial advice.
Positive
- New programmatic connection between OptimizeRx EHR network and DSPs
- Access to programmatic market estimated at 90% of U.S. digital display ad spend
- Enables authenticated, bot-free EHR inventory for life sciences marketers
- Supports DSPs in targeting the $19B+ pharma digital ad market
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
OPRX was down 2.87% while peers were mixed: SPOK +0.37%, TBRG +0.31%, NRC -0.05%, DH -9.27%, SY -2.3%, pointing to a stock-specific move rather than a sector-wide trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | ESG report release | Positive | +1.5% | Publication of 2026 ESG report with expanded emissions disclosure. |
| Apr 28 | Earnings call scheduling | Neutral | -0.2% | Announcement of Q1 2026 conference call date and access details. |
| Apr 16 | External board appointment | Neutral | +8.0% | Myomo appoints former OPRX executive William Febbo to its board. |
| Apr 08 | Board refresh | Positive | -5.2% | Appointment of experienced healthcare and tech leader to OPRX board. |
| Mar 05 | Earnings and guidance | Positive | -10.5% | Strong 2025 results, record Q4 EBITDA, and 2026 guidance with buyback. |
Positive corporate developments, including strong earnings and strategic board changes, have sometimes seen negative price reactions, while more neutral items like ESG reporting or routine calls have produced modest or mixed moves.
Over the last few months, OPRX reported strong 2025 results with growing revenue and EBITDA, authorized a $10M share repurchase, and issued 2026 guidance. Governance and strategy steps included appointing Mary Varghese Presti to the board and publishing a 2026 ESG report. Despite fundamentally positive earnings, shares sold off after that release, while reactions to governance and scheduling news have been mixed, underscoring uneven sentiment around execution and valuation.
Market Pulse Summary
This announcement extends OPRX’s EHR network into DSP programmatic workflows, aiming at a market estimated at 90% of U.S. digital display spend and a $19B+ pharma digital ad segment. It deepens the company’s presence at the point of care and complements prior moves toward a product-led, recurring-revenue platform. Investors may track adoption by life sciences buyers, contribution to revenue growth, and how effectively this channel differentiates OPRX from health information peers.
Key Terms
ehr medical
programmatic buying technical
omnichannel technical
point of care medical
AI-generated analysis. Not financial advice.
Expands life sciences marketers’ reach at the validated point of care, enabling DSPs to directly integrate with OptimizeRx’s trusted EHR network for the first time
WALTHAM, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the most important decision points, today announced the launch of a new programmatic connection point between OptimizeRx’s proprietary EHR network and DSPs, enabling media buyers to activate scalable, point of care campaigns within their existing programmatic workflows. This launch also opens up new access for OptimizeRx to the programmatic market, estimated at
Bridging Point of Care Impact and Programmatic Efficiency
Life sciences media buyers have long faced a tradeoff: activate high-impact campaigns within the EHR through managed programs or buy programmatically with limited or unverified access to real clinical decision moments.
With this launch, media buyers can now combine the speed, control, and transparency of programmatic buying with the precision to reach HCPs directly in their clinical workflow.
Media buyers will be able to:
- Activate EHR campaigns faster, directly through their DSP
- Self-manage the reach, frequency, and scale of EHR placements
- Seamlessly incorporate EHR advertising into their omnichannel strategies
“The EHR is one of the most impactful places to engage HCPs, but not every life sciences brand has a practical way to access it,” said Steve Silvestro, Chief Executive Officer at OptimizeRx. “This launch changes that picture. Not only does it expand access to key clinical moments, but it also represents a step-change for DSPs seeking a competitive advantage in the life sciences market, opening the door to new demand, stronger client relationships, and higher industry revenues.”
Expanding DSP Value in the Life Sciences Market
DSPs can now integrate OptimizeRx’s EHR publisher network directly into their native platform environment, giving their life sciences clients access to premium point of care inventory within existing buying workflows.
By connecting OptimizeRx’s proprietary EHR network to their programmatic platforms, DSPs can:
- Provide marketers with authenticated, bot-free EHR inventory previously unavailable at scale
- Differentiate their offerings with a high-value channel tailored to the needs of their life sciences clients
- Capture an increased share of the
$19B + pharma digital ad market by meeting the demand for greater point of care access
To inquire about integrating OptimizeRx into your programmatic platform, contact: Louis Trivento, SVP Strategic Partnerships, ltrivento@optimizerx.com.
About OptimizeRx
OptimizeRx is a leading healthcare technology company that’s redefining how life sciences brands connect with patients and healthcare providers. Our platform combines innovative, AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood® Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.
Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.
For more information, follow the Company on LinkedIn or X, or visit www.optimizerx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "enabling", "can", "activate", "expanding", "incorporate", "connecting" or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the ability of OptimizeRx to successfully penetrate the programmatic market, a DSP’s ability to expand access to key clinical moments or gain a competitive advantage in the life sciences market, the ability of healthcare marketers to activate point of care campaigns at scale, and a DSP’s ability to better differentiate its offerings or capture greater market share by accessing the EHR network. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions regarding the Company's business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with eRx platforms and EHR networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
OptimizeRx Contact
Jennifer Dinkel, VP Marketing
jdinkel@optimizerx.com
Investor Relations Contact
Douglas Farrell
LifeSci Advisors, LLC
dfarrell@lifesciadvisors.com
Press Inquiries
Matter Communications
optimizerx@matternow.com
Partnership Inquires
Louis Trivento, SVP Strategic Partnerships
ltrivento@optimizerx.com
